Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarfaraz K Niazi

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Frontiers in Artificial Intelligence|January 28, 2026
Beyond mimicry: a framework for evaluating genuine intelligence in artificial systemsSarfaraz K Niazi
Clinicoeconomics and Outcomes Research : CEOR|April 20, 2023
Biosimilars Adoption: Recognizing and Removing the RoadBlocksSarfaraz K Niazi
Life Sciences|August 14, 2025
Telomere-targeted medicine: Bridging molecular mechanisms and clinical applications in age-related diseasesSarfaraz K Niazi
Computational and Structural Biotechnology Journal|August 12, 2025
Dynamic energy conversion in protein catalysis: From brownian motion to enzymatic functionSarfaraz K Niazi
International Journal of Molecular Sciences|July 12, 2025
FINCHES: A Computational Framework for Predicting Intermolecular Interactions in Intrinsically Disordered ProteinsSarfaraz K Niazi
International Journal of Molecular Sciences|July 12, 2025
Quantum Mechanics in Drug Discovery: A Comprehensive Review of Methods, Applications, and Future DirectionsSarfaraz K Niazi
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of BiosimilarsSarfaraz K Niazi
International Journal of Molecular Sciences|September 28, 2024
Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs-Protocols and Advice for the FDA to Meet the ALS Act VisionSarfaraz K Niazi
Pharmaceuticals (Basel, Switzerland)|November 27, 2024
Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not ProvenSarfaraz K Niazi
Drug Design, Development and Therapy|September 13, 2023
The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA PerspectivesSarfaraz K Niazi
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Frontiers in Artificial Intelligence|January 28, 2026
Beyond mimicry: a framework for evaluating genuine intelligence in artificial systemsSarfaraz K Niazi
Clinicoeconomics and Outcomes Research : CEOR|April 20, 2023
Biosimilars Adoption: Recognizing and Removing the RoadBlocksSarfaraz K Niazi
Life Sciences|August 14, 2025
Telomere-targeted medicine: Bridging molecular mechanisms and clinical applications in age-related diseasesSarfaraz K Niazi
Computational and Structural Biotechnology Journal|August 12, 2025
Dynamic energy conversion in protein catalysis: From brownian motion to enzymatic functionSarfaraz K Niazi
International Journal of Molecular Sciences|July 12, 2025
FINCHES: A Computational Framework for Predicting Intermolecular Interactions in Intrinsically Disordered ProteinsSarfaraz K Niazi
International Journal of Molecular Sciences|July 12, 2025
Quantum Mechanics in Drug Discovery: A Comprehensive Review of Methods, Applications, and Future DirectionsSarfaraz K Niazi
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of BiosimilarsSarfaraz K Niazi
International Journal of Molecular Sciences|September 28, 2024
Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs-Protocols and Advice for the FDA to Meet the ALS Act VisionSarfaraz K Niazi
Pharmaceuticals (Basel, Switzerland)|November 27, 2024
Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not ProvenSarfaraz K Niazi
Drug Design, Development and Therapy|September 13, 2023
The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA PerspectivesSarfaraz K Niazi
Pageof 7